Active, not recruitingPHASE1, PHASE2NCT03326336
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Studying Retinitis pigmentosa-juvenile cataract-short stature-intellectual disability syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GenSight Biologics
- Principal Investigator
- GenSight BiologicsGenSight Biologics
- Intervention
- Gene therapy: GS030-DP AND Medical device: GS030-MD(combination_product)
- Enrollment
- 10 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2018 – 2027
Study locations (3)
- UPMC Eye Center, Pittsburgh, Pennsylvania, United States
- Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts, Paris, France
- Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03326336 on ClinicalTrials.gov